Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
66.4M
-
Number of holders
-
169
-
Total 13F shares, excl. options
-
68M
-
Shares change
-
+1.39M
-
Total reported value, excl. options
-
$2.94B
-
Value change
-
+$57.2M
-
Put/Call ratio
-
0.1
-
Number of buys
-
84
-
Number of sells
-
-74
-
Price
-
$43.33
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q1 2024
204 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q1 2024.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 169 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68M shares
.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (7.75M shares), BlackRock Inc. (6.53M shares), BAKER BROS. ADVISORS LP (6.4M shares), RA CAPITAL MANAGEMENT, L.P. (5.33M shares), GOLDMAN SACHS GROUP INC (5.11M shares), VANGUARD GROUP INC (3.3M shares), PERCEPTIVE ADVISORS LLC (3.27M shares), STATE STREET CORP (3.01M shares), NEA Management Company, LLC (2.91M shares), and Frazier Life Sciences Management, L.P. (2.19M shares).
This table shows the top 169 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.